All of this, and yet somehow the share price is the same as a year ago, LOL:
On November 30, 2020, Enzolytics, Inc. (the “Company”) entered into a Business Combination Agreement with Bioclonetics Immunotherapeutics, Inc., (“Bioclonetics”) a Texas Corporation controlled by Charles S. Cotropia, the Company’s current Chief Executive Officer. As consideration for the Business Combination, and in exchange for 100% of the issued and outstanding stock of BioClonetics, the Company has agreed to issue a total of 204,430,000 newly issued shares of Series B Preferred Stock to Charles S. Cotropia, and other Bioclonetic’s Designees and 90,570,000 shares of newly issued Series B Preferred Stock to Harry Zhabilov, the Company’s current Chief Financial Officer. These shares were issued on December 7, 2020. In addition, on November 30, 2020, the Zhabilov Trust, the Company’s Controlling Shareholder, entered into a Control Block Transfer Agreement, under which the Zhabilov Trust has agreed to transfer 35,100,000 shares of Series A Preferred Stock and 231,000,000 shares of Common Stock (together the “Control Block”) to Charles S. Cotropia and other Bioclonetic’s Designees. This reallocation of shares from Zhabilov Trust was completed on December 31, 2020. After such share issuances and transfers we completed, Charles S. Cotropia became the Company’s new Control Block holder and majority shareholder, in addition to his role as Chief Executive Officer of Enzolytics, Inc., resulting in a Change of Control. In addition, on November 16, 2020 the Company entered into debt exchange agreements with Seacor Capital, Inc., and Sky Direct, LLC whereby the balance of their outstanding notes and accrued interest were exchanged for Preferred Series C shares of ENZC extinguishing the debt obligation. As a result of the reorganization, in accordance with Section 251(g) of the DGCL, the remaining convertible and nonconvertible debt of ENZC is now debt of the Predecessor and payable by or convertible into shares of the non-public subsidiary. Page 11 of 21 Pursuant to the terms of the Business Combination Agreement, on November 24, 2020, the Company formed two new Texas corporations as wholly-owned subsidiaries for the purpose of licensing certain patented technologies: Biogenysis, Inc. and Virogentics, Inc. Two Patent License Agreements On November 30, 2020, Biogenysis, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with Bioclonetics in order to license the U.S. Provisional Patent Application No. 63/078,482, filed September 15, 2020, entitled NOVEL HIV-BINDING PEPTIDES for treating, preventing and reducing the risks of HIV, including all patents issuing therefrom and any foreign counterparts thereof. Also on November 30, 2020, Virogentics, Inc., a wholly-owned subsidiary of Enzolytics, Inc., entered into a Patent License Agreement with the Zhabilov Trust in order to license the U.S. Patent No. 7,479538, entitled Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition the same for detecting preventing and treating HIV; U.S. Patent No. 8,066982, Irreversibly - Inactivated pepsinogen fragment and Pharmaceutical composition compressing the same for detecting preventing and treating HIV, including all patents issuing therefrom and any foreign counterparts thereof. Provisional Patent for Immunotherapy Treatment of Multiple Sclerosis On December 9, 2020 the company filed a provisional patent with the U.S. Patent Office for an Immunotherapy treatment of Multiple Sclerosis developed by Harry Zhabilov, titled NUCLEAR PROTEINS ISOLATED FROM MAMALIAN SPINAL CORD (SCNP) IMMUNE FACTOR, Ser. No. 62/123341. The Company received confirmation of filing from the U.S. Patent Office on December 10, 2020. On January 19, 2021 the Company announced the receipt for the Multiple Sclerosis Patent Application. Engagement of BTS Research for Planned Toxicity Test On December 14, 2020, the Company engaged SAMM SOLUTIONS, INC. (DBA BTS Research), through a Master Service Agreement ("MSA"), to conduct a toxicity study on the Company's Flagship compound ITV-1. The Company has previously tested the compound in successful Clinical Trials in Bulgaria, but FDA regulations require separate Toxicity tests before an Investigational New Drug process may begin in the United States. The Company is still in the planning stages and based on the Mutual Recognition Agreement between the European Medicines Agency and the U. S, Federal Drug Administration may pre-empt the need for additional planned toxicity study. The toxicity study has not begun yet. Texas A&M Facilities Effective December 1, 2020, the Company entered a lease with Texas A & M University for office and laboratory space on the campus of Texas A&M University in the University's Institute for Preclinical Studies in order to expand the Company’s development capabilities for the production of additional monoclonal antibodies. Engagement of PCAOB Auditor for December 31, 2020 and 2019 On January 11, 2021, the Company engaged Malone Bailey to perform the Audit for the years ended December 31, 2019 and 2020. The Company completed the client approval process in early February. The audit of both years is still in process. No unanswered issues have arisen. It was determined in June of 2021 that the Bioclonetics transaction, which closed in November of 2020, should be accounted for as a reverse merger rather than a business combination and will be reported as such in the audited financials for ENZC. The requested change in accounting method required the books and records of Bioclonetics to be audited for the years ended December 31, 2019 and 2020 in accordance with GAAP standards by a PCAOB auditor. After the hiring of independent Accounting Consultants, it was determined that the Companies did do a business combination not a reverse merger, and as of the time of this filing, the Company has provided all the records and agreements, accounting memos and backup documentation requested by the consultant and the auditor. The Changes in Accounting Method will result in amendments to the quarters ending March 31. 2021, June 30, 2021 and September 30, 2021 immediately upon completion of the audits. There are no disagreements with the auditing firm and the Company is working closely with all parties to finalize the audit. Page 12 of 21 Discovery of Seven Newly Identified Conserved Target Sites of the HIV Virus. On February 1, 2021, the Company announced the discovery, using Artificial Intelligence, seven hew expected immutable sites on the virus. In Vitro Test Results for ITV-1 Against Human Corona Virus 229E Strain (HCoV-229E) In Vitro test result on the ITV-1 peptide treatment against human corona virus strain 229-E from the Bulgarian National Centre of Infectious and Parasitic Diseases conducted by Petia Genova-Kalou were reported on February 16, 2021. The test results exhibited comparable efficiency but with 20-fold lower toxicity than the widely used anti-influenza medicine, Tamiflu. Formation of International Medical Partners (IMBL) a Bulgarian Limited Liability Company On February 22, 2021, the Company, along with its Bulgarian Partners, executed the Articles of Association to form International Medical Partners. The Company is a 50% owner of IMPL. Clinical Trial under the European Medicines Agency guidelines for the ITV-1 compound are being planned which the Bulgarian Partners are funding. The Company will be providing the necessary vials for testing. On May 7, 2021, the certificate of incumbency with the required apostille was received by IMPL and the final step necessary for the completion of the registration in Bulgaria was completed. Discovery of Eleven Newly Identified Conserved Target Sites of the SARS-CoV-2 Virus (Coronavirus). On February 22, 2021, the Company announced the discovery and Patenting, using Artificial Intelligence, of eleven new expected immutable sites on the SARS-Co-V-2 (Coronavirus) virus. The patents are described as CORONAVIRUS ANTIGENS AND EPITOPES AND PROTEINS THAT BIND THERETO, U.S. Application No. 63/152,084, Filing Date: February 22, 2021. The application covers discoveries relating to the field of viral vaccines and therapeutics, and in particular, discloses antigens and epitopes of SARS-CoV-2, the causative agent of COVID-19. The identified antigens and epitopes of SARSCoV-2 (the Coronavirus) claimed as used to produce binding proteins (e.g., antibodies) and in vaccines for treating, preventing, or reducing the risks of infections caused by ß-coronaviruses such as SARS-CoV-2. The application covers and claims discovered highly conserved antigens and epitopes of SARS-CoV-2, binding proteins (e.g., antibodies) that bind to the disclosed antigens and epitopes, vaccines based on the antigens, and methods of treating, preventing, or reducing the risks of infection with the antigens or binding proteins. Distribution and Operational Agreement with IMBL On March 16, 2021, the Company finalized the operational agreement with IMBL and a distribution agreement for the territories of the Member Countries of the European Medical Agency and the countries of Russia, Georgia, Ukraine, Moldova, Belarus, Armenia, Azerbaijan, Kazakhstan, Uzbekistan, Turkmenistan, Kyrgyzstan, Tajikistan, Estonia, Latvia, and Lithuania. Provisional Patent for Monoclonal Antibodies On March 18, 2021, the company filed a provisional patent with the U.S. Patent Office for Eight newly identified conserved target sites on the HIV-1 virus. The Patens are described as HUMAN IMMUNODEFICIENCY VIRUS (HIV) ANTIGENS AND EPITOPES AND PROTEINS THAT BIND THERETO, U.S. Application No. 63/162,853, Filing Date: March 18, 2021 The patent application is in the field of viral vaccines and therapeutics. It discloses and claims discovered antigens and epitopes of the human immunodeficiency virus (HIV), the causative agent of acquired immunodeficiency syndrome (AIDS). These antigens and epitopes of HIV are disclosed as used to produce binding agents (e.g., antibodies) and in vaccines for treating, preventing, or reducing the risk of HIV infection and the development of AIDS. Page 13 of 21 The application covers and claims discovered highly conserved antigens and epitopes of human immunodeficiency virus (HIV), binding agents (e.g., antibodies) that bind to the disclosed antigens and epitopes, vaccines based on the antigens, and methods of treating, preventing, or reducing the risks of HIV infection with the antigens or binding proteins. Filing of Updated NIH Grant Application On March 22, 2021, the Company filed an updated NIH Grant application incorporating the newly conserved epitotes on both the HIV-1 and SARS-CoV-2 (coronavirus). Issuance of Distributorship for India and multiple Eastern European Countries. On May 12, 2021, the Company granted a distributorship license to a European pharma entity giving it the right to distribute the Company's anti-HIV-1 therapeutic ITV-1 in the countries of India, Pakistan, UAE, Indonesia, Philippines, Nigeria, Benin and Togo, Kenya, Tanzania, Rwanda, Libya, Uganda, North Sudan, Egypt, Morocco, and Tunisia. The Licensing Entity is the owner of a pharmaceutical plant in Eastern Europe. Pursuant to the Agreement, Enzolytics will receive $1 Million USD and 50% ownership in the Licensing Entity valued at $8 Million. The License is granted with a commitment by the Licensee to sale and distribute the ITV-1 therapeutic in the Licensed Territory. In addition, the Licensing Entity has invested $2 Million USD in the Company in exchange for Company Preferred Series E stock bringing to the Company $3 Million in cash plus a 50% ownership in the Licensing Entity. This agreement will result in establishing a committed partner for sale and distribution of the Company's ITV-1 therapeutic in the Licensed Territory as well as 50% ownership in Licensee and its profit derived from sales in the Licensed Territory. Enzolytics, Inc. and Intel Corporation White Paper on Use of Artificial Intelligence On May 17, 2021, Enzolytics Inc. and Intel Corporation published a thought leadership collaboration. The white paper titled, "Optimizing Empathetic A.I. to Cure Deadly Diseases," highlights Intel's Artificial Intelligence Analytic tools and Enzolytic's innovative approach and groundbreaking contributions to create universal, durable, and broadly effective treatment targeting all virus variants. Discovery of Conserved Immutable Target Sites on HTLV-1 Virus The Company announced on May 26 that it had identified conserved, expectedly immutable sites on the HTLV-1 virus against which it will produce targeted anti-HTLV-1 monoclonal antibodies (mAbs). There are no effective vaccines against HTLV-1 and no antiviral drugs available for treating infections caused by the virus. Utilizing the Company's proprietary Artificial Intelligence (AI) methodology, conserved target sites have now been identified against which fully human antiHTLV-1 monoclonal antibodies will be produced in its lab on the campus of Texas A&M University in the University's Institute for Preclinical Studies. Additional Subscription of Preferred Series C On June 6, 2021, Enzolytics CEO invested an additional $100,000.00 in a subscription for Series C Preferred shares. Enzoytics, Inc. and International Medical Partners Ltd Engage Pharmalex, Clinic Design, Ltd. and Danhson Ltd for ITV-1 Clincal Trials and Permitting Process On June 14, 2021, the Company announced the engagement by International Medical Partners Ltd (“IMPL”) of the Contract Research Organization (CRO) Clinical Design, Ltd and PharmaLex to prepare and establish a drug development program for the creation of protocols for human clinical trials that will lead to the licensing of the Company's ITV-1 therapeutic under the European Medicine Agency (EMA). The Company has contracted Danhson Ltd. to produce the initial quantities of ITV-1 to be used for preclinical and clinical trial purposes. Board of Directors Appoints New Members On June 16, 2021, the Company appointed Dr. Joseph P. Cotropia its Chief Science Officer and Dr. Gaurva Chandra its Chief Operating Officer to its Board of Directors. Page 14 of 21 VetProm Site Visit On July 22, 2021, Chief Science Officer, Harry Zhabilov (“Zhabilov”) completed ENZC’s second visit to Sofia, Bulgaria where Zhabilov and ENZC’s Bulgarian and US Consultants toured the manufacturing facility of VetProm, JSC (VetProm”) , a wholly owned subsidiary of Danhson, LTD. This facility will be producing the ITV-1 compound for the clinical trials being conducted by Clinical Design Ltd. and all ENZC’s future production needs. ENZC has purchased and shipped specialized equipment for installation at the facility as part of the manufacturing line for the ITV-1 immunotherapy treatment as well as the raw materials needed for the first clinical trial batch. Appointment of Steve Sharabura as President of RobustoMed On July 26, 2021 Steve Sharabura was appointed President of RobustoMed, Inc. RobustoMed received initial funding on November 12, 2021 for the implementation of its business plan to develop international markets for the Company’s products in Central and Latin America. Agreement entered with Danhson and Clinic Design for Clinical Trials Enzolytics, Inc. completed arrangements and agreements with Danhson (https://danhson.bg/en/) and Clinic Design (https://clinicdesign.eu/) on July 29, 2021 to advance its anti-HIV therapeutic ITV-1 to production and clinical trials. These steps are prefatory to approval by the European Medicines Agency (EMA), leading to patient use authorization. Master Service Agreement (“MDSA”) and Product Specific Agreement – Development and Manufacturing Services (”PSA”) entered into between Samsung Biologics Co., LTD. and Enzolytics, Inc. On October 7, 2021, the Company entered into a MDSA and PSA with Samsung Biologics Co., Ltd to advance the development of the Company’s human clone antibody program and clinical testing. Installation of Equipment at VetProm Facility Enzolytics, Inc. purchased and installed equipment necessary for production of the ITV-1 immunotherapy for the clinical trials being design by Clinic Design. The original equipment had to be returned because of damage to the centrifuge which, along with other issues encountered by IMPL, delayed the scheduled production expected in October. The new expected production date has been rescheduled for January of 2022. Initial Funding for RobustoMed, Inc. On November 12, 2021 RobustoMed, Inc. received the first funding for use in the implementation of its business plan to establish a foothold in Latin and Central America. Enzolytics, Inc. Announces Production and Sale in North America of "Enzolytics IPF Immune", a Tested Immune Modulator based on U.S. Patent No. 8,309,072 On November 17, 2021 announced planned production and sale in the U.S. and North America of "Enzolytics IPF Immune", a liquid nutritional supplement that is an immune modulator that benefits the immune system by fortifying it against infections and supporting the body's antioxidant defense. The active components in the supplement have been registered with the FDA for use in the U.S. under NDI reg. no. 1083. The product will be produced and sold by the Company pursuant to its license under U.S. Patent No. 8,309,072 (the ‘072 Patent). Enzolytics Reports Its Engagement of Scendea USA, Inc., a Leading International Product Development and Regulatory Consulting Group, To Guide the Progress Toward Clinical Trials and Market Approval for Its Itv-1 Anti-HIV Therapeutic On December 29, 2021, Enzolytics, Inc. engaged Scendea USA, Inc. (www.scendea.com), a leading international product development and regulatory consulting group, to advance its anti-HIV therapeutic ITV-1 to production, clinical trials and market approval under both the European Medicines Act (EMA) and the U.S. FDA regulatory process. Scendea is a leading product development and regulatory consulting group serving the pharmaceutical and biotechnology industry. Scendea's service will focus on reducing time-to-market and minimizing development costs. Page 15 of 21 Enzolytics, Inc. Announces Production and Sale in North America of “Enzolytics IPF Immune(TM)”, A New Dietary Supplement That Enhances the Immune System January 4, 2022, the Company announced the production and sale in the U.S. and North America of "Enzolytics IPF Immune™," a science-backed liquid nutritional supplement that acts to strengthen the body's immune system. The immune modulator benefits the immune system by fortifying it against infections. Enzolytics Announces Its New Technology For Entry Into The In-Vitro Diagnostics Market Enzolytics announced its plans for entry into the diagnostics market on February 21, 2022. The Company filed a comprehensive U.S. and foreign Patent Cooperation Treaty (PCT) Patent Application covering its invention of a novel, innovative technology for improved diagnostics. The PCT Application covers the Company's identification of highly conserved antigens and epitopes of SARS-CoV-2 that can be used in vaccines and to produce bindings proteins (e.g., antibodies) for treating, preventing, or reducing the risks of infections caused by ß-coronaviruses such as SARS-CoV-2. The patent also covers the discovery of using these identified antigens and epitopes as targets for detecting and diagnosing SARS-CoV-2 infection. Enzolytics, Inc. Announces New Advisory Board Member On February 28, 2022, Dr. Suraj Kumar Saggar accepted an invitation from the Company to join its Advisory Board. Dr. Saggar brings to the Company his vast experience as a physician and healthcare research professional with an established track record of exceptional performance in healthcare operations, clinical trials, and regulatory compliance. Enzolytics IPF Immune(TM), an Immune Modulator, Is Introduced into the U.S. Market On March 10, 2022 the Company announced that Enzolytics IPF Immune™, its immune modulator, will be introduced into the U.S. market in late March 2022. Enzolytics, Inc.'s Wholly Owned Subsidiary Virogentics, Inc. Reports Progress on the Delivery of its ITV-1 AntiHIV Therapeutic for Use by Patients in African Regions On March 14, 2022 . the wholly-owned subsidiary Virogentics, Inc. (the "Subsidiary") of Enzolytics announced its progress toward the production and use of its ITV-1, anti-HIV immunotherapy treatment in the Central and Eastern regions of Africa for patients with HIV/AIDS. The steps necessary for the production and delivery of the Company's anti-HIV therapy in these regions are in progress. Toxicology, pharmacodynamic and pharmacokinetic studies (toxicology studies) of the immunotherapy are planned, a prerequisite to use of the immunotherapy in certain African countries where the therapies will be used. Enzolytics Highlights Its Comprehensive PCT Patent Applications Covering Discovered Conserved Target Epitopes on the SARS-CoV-2 and HIV Viruses In the submissions, under the Patent Cooperation Treaty (PCT), Enzolytics, Inc. has pending in its international patent applications, covering the use of any of its discovered numerous conserved Coronavirus epitopes or conserved HIV epitopes in the production of monoclonal antibodies, the production of vaccines or use in diagnostic tests for detecting the viruses in patients the applications allow the Company to prosecute the applications both in the U.S. and in all PCT member countries. The applications identify and claim the conserved, immutable sites on the SARS-CoV-2 virus and HIV virus that have been identified by the Company through its Artificial Intelligence (AI) technology. B. Please list any subsidiaries, parents, or affiliated companies. The Company is a 49% owner of the Bulgarian entity IMMB BG, which held a sub-license agreement issued by ENZC for the proprietary immunotherapy treatment until it was terminated in the second quarter of 2021. The Company is 100% owner of Biogenysis, Inc. The Company is 100% owner of Virogentics, Inc. The Company is 100% owner of RobustoMed, Inc. The Company is 100% owner of BioClonetics Immunotherapy, Inc. Page 16 of 21 C. Describe the issuers’ principal products or services, and their markets. The Company’s products consist of multiple distinct drug development proprietary technologies: Immunotherapy, immune modulators, fully human monoclonal antibodies and an artificial intelligence (AI) platform heath care development. Enzolytics has proprietary technology for creating human cell lines that produce fully human monoclonal antibodies against numerous infectious diseases, including HIV-1, Hepatitis (A, B, C), rabies, influenza A and B, tetanus and diphtheria. The Company’s technology for producing fully human monoclonal antibodies is now being employed to produce anti-SARSCoV-2 (Coronavirus) monoclonal antibodies for treating COVID-19. The Company plans to employ its technology to subsequently produce fully human monoclonal antibodies for treating HIV-2, anthrax, smallpox, H1N1 influenza, herpes zoster, varicella zoster, Rh (+) auto-immune disease and the Ebolavirus. The Company is in the final development of the recombinant of the parent anti-HIV monoclonal antibody (identified as “Clone 3”) which has been shown in in vitro tests conducted in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. The basis for its broad-spectrum efficacy is the fact that Clone 3 antibody targets an immutable epitope on the HIV virus. The targeted epitope has remained present in 98% (either directly or by way of conserved substitutions) of the 87,336 HIV isolates now known which have been analyzed by the Company using Artificial Intelligence (AI). Using AI, the Company has also identified 8 additional conserved sites on the HIV-1 virus, some with over 98% conserved sequences, against which the Company plans to produce anti-HIV monoclonal antibodies. Production of multiple antibodies targeting different conserved and expectedly immutable sites comports with experts’ conclusion that an effective treatment for HIV and the Coronavirus will likely require the administration of multiple monoclonal additional antibodies. Effective monoclonal antibodies will be those that target conserved and expectedly immutable virus sites. Producing targeted antibodies will result in the production of a therapeutic that will not be rendered ineffective due to mutation (variants) of the virus. In other words, even a “variant form of the virus” will expectedly contain the immutable targeted sites. Targeting immutable sites avoids the ineffectiveness that is experienced when a therapeutics or vaccine targets a site that nutates. While the Company’s HIV therapeutics may be used as an immunotherapeutic treatment for individuals with HIV/AIDS, they may also be developed for use as a prophylactic and therapeutic vaccine to prevent uninfected populations from contracting the HIV virus. Treatment using the fully human anti-HIV antibody will be far superior to current antiretroviral therapy for several significant reasons: (1) the therapy will be non-toxic (without damage to the kidneys and liver) and will not cause bone density deterioration (osteopenia and osteoporosis) – as does antiretroviral treatments, (2) will not require lifetime treatment and (3) will be far less expensive. Using its proprietary methodology, the Company is also producing anti-SARS-CoV-2 monoclonal antibodies and has identified 19 conserved, expectedly immutable epitopes on the Coronavirus against which it plans to produce targeted monoclonal antibodies. Using AI, the Company has screened over 2 Million Coronavirus isolates currently known and has identified conserved sites which expectedly are immutable. The 19 conserved sequences identified on the virus isolates curated have been identified on the basis that they are 98.71% to 99.29% conserved over the entirety of the 50,512 Coronavirus isolates analyzed by the Company using AI. Comprehensive patent protection covering these discoveries, relating to HIV, the Coronavirus, and use of AI to guide production of antibodies have been filed under the Patent Cooperation Treaty (PCT) to seek coverage in the U.S. and in member countries of the PCT, In these PCT Patent Applications, the Company has claimed its discoveries relating to both HIV and the SARS CoV-2 (Coronavirus) including the use of these identified conserved epitopes for (1) producing a therapeutic monoclonal antibody to treat HIV or the CoronaVirus, (2) producing a vaccine against HIV or the CoronaVirus, or (3) for use in any diagnostics to identify whether a person has HIV or the CoronaVirus. In this way, the patent coverage sought includes patent claims on the discovered epitope/antigens, vaccine claims, antibody claims, and related prophylactic/therapeutic method claims relating to the epitope/antigens. The Coronavirus treatment drug market is expected to grow from 15.9 billion in 2020 to over $49.2 billion in 2027. The HIV Drug Market is expected to reach $36.49 billion by 2027 for a total market size of $85.69 for the treatments under development, The Company expects, aided by the continued use of AI, further expansion of its pipeline of additional treatments for other life threatening and debilitating viruses both in humans and in animals. Page 17 of 21 Another therapeutic newly introduced into the U.S. market by the Company is an immune modulation sold under the brand IPF Immune™. Enzolytics IPF Immune™ is an immune modulator which stimulates the immune system to help protect people from infections and diseases, enhances recovery and reduces the recovery period after an illness. It has a beneficial effect on the immune system, enhancing the body’s ability to fight infections, promoting antibody production, and promoting the body’s antioxidant defenses. Enzolytics IPF immune targets the infected cell and increases the natural immune response to destroy the infected cells. It acts by tagging viruses to assist T-cells to address them. In this way, it assists the body’s immune helper T-cells in performing their natural function. The protection process that is stimulated is natural and produces no side effects. The following attributes have been identified as provided by the IPF Immune therapeutics: • Enzolytics IPF Immune™ may be combined with anti-inflammatory drugs, antiviral, antibacterial, and antimycotic treatment to support the immune system. • IPF has similar clinical benefit of Acyclovir (for treating Herpes), Tamiflu (for treating Influenza) but those therapies were found to be 35 times more toxic to the body. • Beneficial in viral diseases: viral hepatitis, influenza, cytomegalovirus or herpes infections. oncological diseases. complex therapy of infectious-inflammatory diseases, and opportunistic infections. • Beneficial in non-specific pulmonary infections such as pneumonia, chronic obstructive pulmonary disease, chronic bronchitis, laryngitis, or laryngotracheitis. Balancing the work of the immune system after influenza infections or coronaviruses infections. • Demonstrated very good tolerance in all patients and absence of side effects
News 
Market Data 
Discover 
